4 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 10 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 4, Recruiting 3, Terminated 2, Active not recruiting 1 |
| Phase 2 | 3 | Completed 3 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer Pasritamig, Docetaxel, Prednisone/Prednisolone - Prostatic Neoplasms, Castration-Resistant | Phase 3 | Recruiting | Janssen Research & Development, LLC | 800 | 2025-12-19 | 2026-09-25 |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) Pasritamig, Placebo, Best Supportive Care (BSC) - Metastatic Castration-resistant Prostatic Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1203 | 2025-09-02 | 2026-09-25 |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy - Prostatic Cancer, Castration-Resistant | Phase 3 | Recruiting | UNICANCER | 336 | 2024-10-07 | 2024-12-20 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer Ga-68 PSMA-HBED-CC PET - Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 6 | 2019-03-01 | 2025-04-17 |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Niraparib, Abiraterone Acetate, Prednisone - Castration-Resistant Prostatic Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 765 | 2019-01-25 | 2026-09-25 |
| 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 30 | 2018-02-16 | 2024-07-12 |
| 68Ga PSMA in Preprostatectomy Patients Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 22 | 2018-02-16 | 2024-02-15 |
| A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Atezolizumab, Enzalutamide - Prostatic Neoplasms, Castration-Resistant | Phase 3 | Completed | Hoffmann-La Roche | 759 | 2017-01-10 | 2024-08-09 |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer Tasquinimod, Placebo - Prostatic Neoplasms, Castration-Resistant | Phase 3 | Terminated | Ipsen | 146 | 2014-01-01 | 2021-04-23 |
Prostatic Neoplasms (4) · Neoplasm Metastasis (1)
Genital Diseases (10) · Genital Diseases, Male (10) · Genital Neoplasms, Male (10) · Male Urogenital Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Prostatic Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Prostatic Neoplasms (6) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Abiraterone Acetate (2) · Prednisone (2) · enzalutamide (2) · Androgen Antagonists (1) · Docetaxel (1) · Prednisolone (1) · Radiosurgery (1) · abiraterone (1) · atezolizumab (1) · darolutamide (1) · niraparib (1) · sabizabulin (1) · tasquinimod (1)
Janssen Research & Development, LLC (3) · Michael Graham PhD, MD (3) · Hoffmann-La Roche (1) · Ipsen (1) · UNICANCER (1) · Veru Inc. (1)
United States (8) · China (5) · France (5) · South Korea (5) · Taiwan (5) · Australia (4) · Belgium (4) · Canada (4) · Germany (4) · Italy (4) · Spain (4) · United Kingdom (4) · Brazil (3) · Japan (3) · Poland (3)
Michael Graham, MD, PhD (1) · Michael M Graham, Ph.D., MD (1) · Michael M. Graham, MD, PhD (1)
PMID 35013615, PMID 36952634, PMID 38958846, PMID 39111209, PMID 39317633, PMID 40016438, PMID 42015879
2023 (2), 2025 (2), 2016 (1), 2017 (1)